Immunological studies in patients receiving Corynebacterium parvum (C.P.) as immunotherapy for acute myelogenous leukemia (AML).

V. Pai,P. Shetty,D. Jussawalla

Indian Journal of Cancer

Abstract:

What problem does this paper attempt to address?

Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated with Anti-Pd-1 Antibody

Yuan Shijin,Xia Yan,Shen Lihong,Ye Liuqing,Li Lisha,Chen Lifen,Xie Xinyou,Lou Haizhou,Zhang Jun

DOI: https://doi.org/10.1007/s00262-020-02710-9

2020-01-01

Abstract:Anti-programmed death-1 (PD-1) antibody changed the treatment of non-small cell lung cancer (NSCLC), however, reliable predictive markers were lacking. We aimed to explore factors associated with response and survival, and develop predictive models. This multicenter retrospective study included a training cohort (n = 92) and validation cohort (n = 111) with NSCLC patients received anti-PD-1 antibody monotherapy in eight Chinese hospitals, and a control cohort (n = 124) with NSCLC patients received chemotherapy. Logistic and Cox models were used to identify factors associated with response and survival respectively. Nomograms were developed based on significant factors, and evaluated by Concordance-index (C-index), area under the curve (AUC) and calibration curve. In training cohort, smoking history (P = 0.027) and higher absolute lymphocyte count (P = 0.038) were associated with response. Female (P < 0.001), age ≥ 65 years (P = 0.004) and higher lactate dehydrogenase (LDH, P < 0.001) were associated with shorter progression-free survival (PFS). Higher LDH (P < 0.001) and derived neutrophil-to-lymphocyte ratio (P = 0.035) were associated with poorer overall survival (OS). While these factors were nonsignificant in chemotherapy cohort. Three nomograms to predict response at 6-week after treatment, PFS and OS at 6-, 12- and 18-months were developed, and validated in validation cohort. The C-indices of each nomogram in both cohorts were as follow (training vs validation): 0.706 vs 0.701; 0.728 vs 0.701; 0.741 vs 0.709; respectively. AUC showed a good discriminative ability. Calibration curves demonstrated a consistence between actual results and predictions. We developed predictive nomograms based on easily available factors to help clinicians early assess response and prognosis for NSCLC patients received anti-PD-1 antibody.
Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

David C. Turner,Russ Wada,Helen Zhou,Xiaowei Wang,Rik de Greef,Chandni Valiathan,Lindsey Zhang,Nancy Zhang,Mita Kuchimanchi,Tai-Tsang Chen,Marc Ballas,Sandra A. G. Visser

DOI: https://doi.org/10.1002/psp4.12917

2023-01-01

Abstract:Single-arm cohorts/trials are often used in early phase oncology programs to support preliminary clinical activity assessments for investigational products, administered alone or in combination with standard of care (SOC) agents. Benchmarking clinical activity of those combinations against other treatments, including SOC, requires indirect comparisons against external trials, which presents challenges including cross-study differences in trial populations/other factors. To facilitate such nonrandomized comparisons, we developed a comprehensive model-based meta-analysis (MBMA) framework to quantitatively adjust for factors related to efficacy in metastatic non-small cell lung cancer (mNSCLC). Data were derived from 15 published studies assessing key programmed cell death protein-1 (PD-1) inhibitors pembrolizumab (n = 8) and nivolumab (n = 7), representing current SOC in mNSCLC. In the first stage, a mixed-effects logistic regression model for overall response rate (ORR) was developed accounting for effects of various population covariates on ORR. The ORR model results indicated an odds ratio (OR) of 1.02 for squamous versus non-squamous histology and OR of 1.20 for PD-ligand 1 tumor proportion score (TPS) per every 10% increase of TPS level. Next, a nonparametric mixed-effects model for overall survival (OS) was developed with ORR/other clinical covariates as input. Subsequently, MBMA simulations of relevant hypothetical scenarios involving single-arm trial design predicted OS hazard ratios as a function of ORR with matched patient characteristics. Findings from this MBMA and derived parameter estimates can be generally applied by the reader as a framework for interpreting efficacy data from early phase trials to support ORR-based go/no-go decisions and futility rules, illustrated through examples in this report.
Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials

Run-Cong Nie,Fo-Ping Chen,Shu-Qiang Yuan,Ying-Shan Luo,Shi Chen,Yong-Ming Chen,Xiao-Jiang Chen,Ying-Bo Chen,Yuan-Fang Li,Zhi-Wei Zhou

DOI: https://doi.org/10.1016/j.ejca.2018.10.011

Abstract:Background: We aimed to assess whether the Response Evaluation Criteria in Solid Tumors (RECIST) criteria-based objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) could be valid surrogate end-points for overall survival (OS) in anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) trials. Methods: We systematically reviewed phase 2 and phase 3 trials of anti-PD-1/PD-L1 drug trials of advanced or recurrent solid tumours that reported OS and at least one of the RECIST criteria-based end-points. We used Spearman rank correlation to evaluate the strength of the association between these end-points and OS and a linear regression model, weighted by the sample size, to assess the association between the treatment effect on these end-points and OS. We also performed sensitivity analyses and a leave-one-out cross-validation approach to evaluate the robustness of our findings. Results: Forty-three qualifying trails comprising 15,088 patients were eligible. PFS showed good correlation with OS (squared Spearman rank correlation coefficient [rs2] = 0.54; P < 0.001), while ORR and DCR illustrated moderate association with OS (rs2 = 0.29 and 0.28, respectively; both P < 0.001). The correlation was moderate between the treatment effects on PFS and OS (coefficient of determination [R2] = 0.37, P < 0.001) and poor among ORR, DCR and OS (R2 = 0.10 and 0.08, respectively); these were confirmed by sensitivity analyses (all R2 < 0.75) and the leave-one-out cross-validation approach. Conclusions: No RECIST criteria-based end-points could be a valid surrogate for OS. At present, we proposed to set OS as the primary end-point in anti-PD-1/PD-L1 drug trials of advanced or recurrent solid tumours.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Peng Song,Xiaoxia Cui,Li Bai,Xiangdong Zhou,Xiaoli Zhu,Jian Zhang,Faguang Jin,Jianping Zhao,Chengzhi Zhou,Yanbin Zhou,Xiaoju Zhang,Kai Wang,Qi Wang,Yao Yu,Xiaoyu Zhang,Chunxue Bai,Li Zhang

DOI: https://doi.org/10.1111/1759-7714.13078

IF: 3.223

2019-01-01

Thoracic Cancer

Abstract:According to multiple studies, the objective response rate of PD-1/PD-L1 inhibitors in the second-line treatment of unscreened non-small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD-L1 expression >= 50%, the response rate of pembrolizumab in first-line treatment can reach 44.8%. Moreover, patients with a higher tumor mutation burden (TMB) tend to achieve a better response with nivolumab. Besides PD-L1 expression and TMB, taking all these indicators into consideration would hypothetically maximize the clinical response in a specific subgroup of patients. Our study aims to accumulate large and complete samples and clinical data to verify the biomarkers and their cutoff values related to the efficacy of PD-1/PD-L1 inhibitors in Chinese NSCLC patients, and to construct a comprehensive predictive model by combining multi-omics data with contemporary machine learning techniques. NSCLC patients administered treatment of anti-PD-1/PD-L1 antibodies or a combination with other drugs have been enrolled. The estimated enrollment is 250 participants. A sophisticated predictive model of immunotherapy response in the Chinese population has not yet been developed. It is clinically and practically imperative to comprehensively evaluate the possible indicators of Chinese NSCLC patients through multiple test platforms, such as next generation sequencing, PCR, or immunohistochemistry. This study is registered in the Chinese Clinical Trial Registry (ChiCTR1900021395).
Abstract 6401: Predictive models for first-line immunotherapy based on spatial tumor immune microenvironment in patients with advanced non-small cell lung cancer (NSCLC)

Chan Xiang,Jianjian Zheng,Sidong Chen,Zhanxian Shang,Shi Yang,Lianying Guo,Lei Jiao,Yang Wang,Yuchen Han

DOI: https://doi.org/10.1158/1538-7445.am2024-6401

IF: 11.2

2024-03-26

Cancer Research

Abstract:Background: Anti-programmed cell death protein 1/programmed cell death ligand 1 (anti-PD1/PDL1) based immunotherapy is the standard first-line treatment for advanced NSCLC patients without targetable driver mutations, but PDL1 immunohistochemistry (IHC) shows limited predictive value as companion diagnostics. Recent studies have elucidated a strong relationship between immunotherapy efficacy and tumor immune microenvironment (TIME) using single-cell multi-omics technology. In this study, we aim to develop predictive models for both objective response rate (ORR) and progression-free survival (PFS) using TIME features with machine learning in advanced NSCLC patients treated with first-line immunotherapy. Methods: A total of 210 patients with advanced NSCLC who received anti-PD-1/PDL-1 therapy at Shanghai Chest Hospital from Jan. 2020 to Jan. 2023 were included in this study. Among them, 110 cases who received pembrolizumab were randomly split into training set and validation set with a 2:1 ratio. The remaining patients were designated as independent validation cohort. Five multiplex immunohistochemistry (mIHC) panels were developed based on literature review and in-house dataset mining. mIHC tests were performed using baseline tumor samples. Immunotherapy efficacy was evaluated by ORR and PFS (RECIST v1.1). ORR and PFS models were developed using machine learning methods in training set with 5-fold cross-validation and further validated in validation set and independent validation cohort. Results: After data cleaning, 68 cases in training set and 34 cases in validation set were further analyzed. In terms of single immune- or spatial- based biomarker, positive rate of PD1+ cells in stroma and spatial relationship of PD1+/PDL1+ cell pairs exhibited the highest correlation with ORR. In addition, positive rate of PDL1+ tumor cells and nearest distance between FOXP3+ cells and tumor cells were highly correlated with PFS. Our ORR model achieved an AUC of 0.82 in the training set and 0.82 in the validation set. When applying optimal cutoff in our PFS model to stratify patients into low- and high- risk groups, low-risk group showed prolonged PFS in both training set (p < 0.0001; HR: 0.25, 95% CI [0.13 - 0.51]) and validation set (p = 0.00046; HR: 0.22, 95% CI [0.09 - 0.55]). Moreover, our ORR model outperformed PDL1 IHC (AUC: 0.81 vs 0.60; DeLong's test p = 0.005) in these 102 patients. Independent validation of the models is still awaited. Conclusion: Using machine learning methods, we developed and validated ORR and PFS predictive models for first-line immunotherapy in advanced NSCLC patients based on mIHC technology. Our models displayed superior diagnostic performance compared to PDL1 IHC results. Citation Format: Chan Xiang, Jianjian Zheng, Sidong Chen, Zhanxian Shang, Shi Yang, Lianying Guo, Lei Jiao, Yang Wang, Yuchen Han. Predictive models for first-line immunotherapy based on spatial tumor immune microenvironment in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6401.

oncology
951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis

X. Wang,M. Ballas,H. Chen,K.F. Bell,A. Slowley,C. Ellis,C. Baccan,D.C. Turner,H. Zhou

DOI: https://doi.org/10.1016/J.ANNONC.2020.08.1066

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:With the successes of immunotherapy development across cancer indications, including anti–PD-(L)1 antibodies, immunotherapy is now a prevailing treatment in HNSCC trials. OS is the gold standard endpoint for evaluating clinical efficacy, especially in pivotal oncology trials, but establishing OS benefit in randomised studies requires large investments. In early phase, single-arm trials, ORR and PFS have been widely used as surrogate endpoints for OS; establishing such surrogate endpoints could improve efficiency of clinical development in terms of patient numbers, time, and cost. The relationship among ORR, PFS, and OS may vary by cancer type, treatment mechanism of action, and disease setting, and has not yet been published for immune-oncology (I-O)–based regimens investigated for recurrent/metastatic (R/M) HNSCC. A systematic review and meta-analysis were conducted to investigate such association among OS, PFS, and ORR in R/M HNSCC. A systematic literature review was performed to identify relevant Phase II and III trials published since 2015 that investigated I-O treatments and I-O/chemotherapy combinations for R/M HNSCC. In total, 40 subpopulations in five trials were included in the meta-analysis. The meta-analysis investigated associations between ORR and log-transformed (LT) median OS (mOS), between ORR and LT median PFS (mPFS), and between LT mPFS and LT mOS. The statistical model was conducted using a weighted linear regression model with weights proportional to sample size of each subpopulation and included therapy line as covariate. A statistically significant linear relationship was identified between ORR and LT mOS (R2=0.78, p<0.0001), and between LT mPFS and LT mOS (R2=0.79, p<0.0001). A weak but statistically significant linear relationship was identified between ORR and LT mPFS (R2=0.26, p=0.018). The meta-analysis showed significant correlation between ORR and OS, and between PFS and OS, supporting ORR and PFS as surrogate endpoints to predict OS effect in early phases of clinical trials evaluating I-O treatments in R/M HNSCC.
Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models

Shuling Shi,Yingyi Wang,Jingjing Wu,Boya Zha,Peihong Li,Yukun Liu,Yuchuan Yang,Jinglin Kong,Shibo Gao,Haiyang Cui,Linkuan Huangfu,Xiaocong Sun,Zhikai Li,Tiansong Liang,Yingjuan Zheng,Daoke Yang

DOI: https://doi.org/10.3389/fonc.2024.1342262

IF: 4.7

2024-05-02

Frontiers in Oncology

Abstract:Objective: To investigate the correlation between programmed death ligand 1(PD-L1), tumor mutation burden (TMB) and the short-term efficacy and clinical characteristics of anti-PD-1 immune checkpoint inhibitor combination chemotherapy in NSCLC patients. The efficacy of the prediction model was evaluated. Methods: A total of 220 NSCLC patients receiving first-line treatment with anti-PD-1 immune checkpoint inhibitor combined with chemotherapy were retrospectively collected. The primary endpoint was short-term efficacy ORR. The correlation between short-term efficacy, PD-L1, TMB, and clinical characteristics using χ2 test or t-test was evaluated. Screen the independent prognostic factors using univariate and multivariate logistic regression analyses, and construct a nomogram prediction model using the "rms" package in R software. Using receiver operating characteristic (ROC) curve analysis to evaluate the independent Prognostic factors and the prediction model. Using decision curve analysis (DCA) to verify the superiority of the prediction model. Results: The mean values of PD-L1, TMB, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio, and albumin were the highest in the ORR group, PD-L1 expression and TMB correlated with epidermal growth factor receptor expression. Multivariate analyses showed that PD-L1, TMB, and neutrophil were independent prognostic factors for ORR. The area under the ROC curve (AUC) values of the ROC constructed based on these three indicators were 0.7104, 0.7139, and 0.7131, respectively. The AUC value under the ROC of the nomogram model was 0.813. The DCA of the model showed that all three indicators used together to build the prediction model of the net return were higher than those of the single indicator prediction model. Conclusion: PD-L1, TMB, and neutrophils are independent prognostic factors for short-term efficacy. The nomogram prediction model constructed using these three indicators can further improve predictive efficacy of ICIs in patients with NSCLC.

oncology
Abstract 6904: Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies

Andrew Chen,Madison Stoddard,Lin Yuan,Debra Van Egeren,Arijit Chakravarty,Dean Bottino

DOI: https://doi.org/10.1158/1538-7445.am2024-6904

IF: 11.2

2024-03-31

Cancer Research

Abstract:Patient-derived xenografts (PDX) are a powerful assay system for translational prediction of therapeutic potential for experimental therapeutics. The primary readout from PDX models is tumor shrinkage, measured by the ratio of treated/control tumor volume. This readout corresponds loosely to the Objective Response Rate (ORR) metric used in clinical trials, in that it is a readout of drug effect on the sensitive subclones within a tumor. In prior work, we have shown that there is a paradoxical relationship between short-term tumor response and progression-free survival (PFS). While ORR is the primary measure utilized in the Phase II to III transition in clinical development, approval hinges on survival metrics, and the disconnect between ORR and PFS creates a potential risk of late-stage failures for experimental anticancer therapeutics. Thus, it is of interest to understand whether there are alternative approaches to analyzing PDX data that can enable the assessment of therapeutic potential in terms of a projected PFS. In this simulation study, we will examine the accuracy of progression-free survival (PFS) estimates obtained directly from observation during a PDX study and compare their accuracy with the accuracy of PFS estimates derived using a mathematical model-based approach that relies on a kinetic model of tumor subclone growth (model-based PFS, or mPFS) fitted directly to PDX tumor growth and rebound kinetics under treatment. We generated our test dataset using a mathematical model of tumor kinetic growth to simulate xenograft data using fitted parameters derived from literature, adding in experimental error consistent with prior experimental measurement-derived variability. We used the simulated raw data to calculate an observed PFS as well as mPFS derived from fitting the tumor clonal kinetic model to the raw data in a blinded fashion. Our results show that the empirical PFS from PDX models is subject to overestimation, as a function of the observation time interval. On the other hand, mPFS is significantly less biased and more accurate, but is subject to some logistical constraints on sampling. Our work demonstrates the practical translational utility of a novel analysis method (mPFS) in deriving estimates of progression-free survival from PDX model data. Citation Format: Andrew Chen, Madison Stoddard, Lin Yuan, Debra Van Egeren, Arijit Chakravarty, Dean Bottino. Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6904.

oncology
Hypoxia-mediated in vivo release of dopamine in nucleus tractus solitarii of rabbits.

M. Goiny,H. Lagercrantz,M. Srinivasan,U. Ungerstedt,Y. Yamamoto

DOI: https://doi.org/10.1152/JAPPL.1991.70.6.2395

1991-06-01

Journal of Applied Physiology

Abstract:A wide variety of neuroactive substances have been suggested to be involved in the respiratory depression observed in response to severe hypoxia. By use of the technique of microdialysis, the release of dopamine (DA) was measured in the nucleus tractus solitarii during severe hypoxic provocations (6% O2 in N2) in the adult pentobarbital-anesthetized rabbit. DA release was analyzed by high-performance liquid chromatography with electrochemical detection. Such hypoxic provocations caused pronounced phase of depression in the phrenic nerve activity and enhanced release of DA. After bilateral carotid sinus nerve denervation, acute severe hypoxia did not give rise to enhanced release of DA or to phrenic nerve depression. Mild hypoxic (9% or 12% O2 in N2) or hypercapnic (6% CO2) stimuli resulted in an increased phrenic nerve activity without any concomitant changes in DA release. Decerebration at the midcollicular level in rabbits prevented an enhanced release of DA in the nucleus tractus solitarii during severe hypoxia. The results suggest that 1) DA is involved in the central ventilatory response to severe hypoxia, 2) not only the initial excitatory but also the second depressive phase in response to severe hypoxia is mediated partially by the peripheral chemoreceptors, and 3) the depressive phase is dependent on intact connections from suprapontine structures.
Stomatogenic function of the micronucleus in Paramecium jenningsi.

M. Chau,S. F Ng

DOI: https://doi.org/10.1016/S0932-4739(88)80007-5

IF: 3.471

1988-12-01

European Journal of Protistology

Abstract:
Risk Models For Advanced Melanoma Patients Under Anti-Pd-1 Monotherapy-Ad Hoc Analyses Of Pooled Data From Two Clinical Trials

Xue Bai,Jie Dai,Caili Li,Chuanliang Cui,Lili Mao,Xiaoting Wei,Xinan Sheng,Zhihong Chi,Xieqiao Yan,Bixia Tang,Bin Lian,Xuan Wang,Li Zhou,Siming Li,Yan Kong,Zhonghui Qi,Huayan Xu,Rong Duan,Jun Guo,Lu Si

DOI: https://doi.org/10.3389/fonc.2021.639085

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:Background: The best response and survival outcomes between advanced melanoma patients treated with the anti-PD-1 monotherapy vary greatly, rendering a risk model in need to optimally stratify patients based on their likelihood to benefit from the said treatment.Methods: We performed an ad hoc analysis of 89 advanced melanoma patients treated with the anti-PD-1 monotherapy from two prospective clinical trials at the Peking University Cancer Hospital from April 2016 to May 2018. Clinicodemographical characteristics, baseline and early-on-treatment (median 0.6 months after anti-PD-1 monotherapy initiation) routine laboratory variables, including complete blood count and general chemistry, and best response/survival data were extracted and analyzed in both univariate and multivariate logistic and Cox proportional hazard models.Results: After three rounds of screening, risk factors associated with a poorer PFS included a high pre-treatment neutrophil, derived neutrophil-lymphocyte ratio (dNLR), low pre-treatment hemoglobin, and low early-on-/pre-treatment fold change of eosinophil; those with a poorer OS included a high pre-treatment neutrophil, eosinophil, PLT, early-on/pre-treatment fold change of LDH and neutrophil; and those with a poorer best response included a high pre-treatment NLR and early-on-/pre-treatment LDH fold change. Risk models (scale: low, median-low, median high, and high risk) were established based on these risk factors as dichotomous variables and M stage (with vs. without distant metastasis) for PFS (HR 1.976, 95% CI, 1.507-2.592, P < 0.001), OS (HR 2.348, 95% CI, 1.688-3.266), and non-responder (OR 3.586, 95% CI, 1.668-7.713, P = 0.001), respectively. For patients with low, median-low, median-high, and high risks of developing disease progression (PD), six-month PFS rates were 64.3% (95% CI, 43.5-95.0%), 37.5% (95% CI, 22.4-62.9%), 9.1% (95% CI, 3.1-26.7%), and 0%, respectively. For patients with OS risks of low, median-low, median-high, and high, OS rates at 12 months were 82.5% (95% CI, 63.1-100%), 76.6% (95% CI, 58.4-100%), 42.1% (95% CI, 26.3-67.3%), and 23.9% (95% CI, 11.1-51.3%), respectively. For patients with risks of low, median-low, median-high, and high of being a non-responder, objective response rates were 50.0% (95% CI, 15.7-84.3%), 27.8% (95% CI, 9.7-53.5%), 10.3% (95% CI, 2.9-24.2%), and 0%, respectively.Conclusion: A risk scoring model based on the clinicodemographical characteristics and easily obtainable routinely tested laboratory biomarkers may facilitate the best response and survival outcome prediction and personalized therapeutic decision making for the anti-PD-1 monotherapy treated advanced melanoma patients in Asia.
Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncology

Marcus Baaz,Tim Cardilin,Mats Jirstrand

DOI: https://doi.org/10.1016/j.ejps.2024.106901

2024-12-01

Abstract:Progression-free survival (PFS) is an important clinical metric in oncology and is typically illustrated and evaluated using a survival function. The survival function is often estimated post-hoc using the Kaplan-Meier estimator but more sophisticated techniques, such as population modeling using the nonlinear mixed-effects framework, also exist and are used for predictions. However, depending on the choice of population model PFS will follow different distributions both quantitatively and qualitatively. Hence the choice of model will also affect the predictions of the survival curves. In this paper, we analyze the distribution of PFS for a frequently used tumor growth inhibition model with and without drug-resistance and highlight the translational implications of this. Moreover, we explore and compare how the PFS distribution for combination therapy differs under the hypotheses of additive and independent-drug action. Furthermore, we calibrate the model to preclinical data and use a previously calibrated clinical model to show that our analytical conclusions are applicable to real-world setting. Finally, we demonstrate that independent-drug action can effectively describe the tumor dynamics of patient-derived xenografts (PDXs) given certain drug combinations.
Abstract 5697: Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data

Hanwen Wang,Theinmozhi Arulraj,Aleksander S. Popel

DOI: https://doi.org/10.1158/1538-7445.am2023-5697

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Introduction: Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer with an overall 5-year survival rate of 26%, which varies by the disease stage. Novel drug combinations involving immune checkpoint inhibitors are being investigated in clinical trials in NSCLC. In this study, we generated about 450 virtual patients that resembled actual patients with NSCLC and simulated tumor growth during PD-L1 inhibition using a quantitative systems pharmacology (QSP) model. Methods: We recalibrated a previously developed QSP model of the cancer-immunity cycle (1) to NSCLC with parameters estimated by published experimental data. Proportions of CD8, CD4, and regulatory T cells (Tregs), M1 and M2 macrophages in lung adenocarcinoma and lung squamous cell carcinoma were downloaded from iAtlas database and used to calculate the ratios of CD8/CD4, Tregs/CD8, and M1/M2. The three immune subset ratios (observed data) were used to guide the virtual patient generation. We first randomly generated deviations around the baseline model parameters to account for inter-patient variability and then selected virtual patients with model-predicted immune subset ratios statistically matching the observed data. Finally, we simulated tumor growth during PD-L1 inhibition and predicted clinical response in the virtual patient cohort. Results: Our model predicted an overall response rate of 16.3% with a 95% bootstrap confidence interval of (11.8, 22.4)% for the overall virtual patient cohort. It also showed that CD8 T cells, PD-L1 expression, CD8/CD4, CD8/Tregs, M1/M2 ratios, and the number of NSCLC-specific T cell clones were significantly higher in responders to PD-L1 inhibition. Furthermore, Tregs/CD8 and CD8/CD4 ratios were predicted to be the best predictive biomarkers according to ROC analysis with areas under ROC curve of 0.71 and 0.66. Conclusion: Immunogenomic analysis of RNA-seq data on iAtlas allowed generation of realistic virtual patients using QSP models in immuno-oncology. With a virtual patient cohort guided by immunogenomic data, our model provided reliable efficacy prediction for immunotherapy and a tool to identify predictive biomarkers in NSCLC. 1. Wang H, Zhao C, Santa-Maria CA, Emens LA, Popel AS. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. iScience. 2022;25:104702. Citation Format: Hanwen Wang, Theinmozhi Arulraj, Aleksander S. Popel. Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5697.

oncology
Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials

Runcong Nie,Foping Chen,Mariano Provencio,Yun Wang,Tom van den Ende,Hanneke W M van Laarhoven,Shuqiang Yuan,Miklos Pless,Stefanie Hayoz,Zhiwei Zhou,Yuanfang Li,Sacha I Rothschild,Muyan Cai

DOI: https://doi.org/10.1016/j.ejca.2023.03.010

Abstract:Background: An increasing number of clinical trials are being conducted exploring the efficacy of neoadjuvant immune checkpoint inhibitors. Surrogate end-points for overall survival (OS) are urgently needed. Methods: Phase II or III trials of neoadjuvant immunotherapy that reported data on OS and surrogate end-points were identified from January 1, 2000, to November 25, 2022. Individual patient data, and trial-level data were requested from corresponding authors or extracted from eligible trials. At the individual level, correlations between radiological and pathological response and OS were measured by the Cox model and quantified by hazard ratio (HR). C-statistic was used to quantify the predictive performance of radiological and pathological response for OS. The coefficient of determination (R2) between RFS and OS was evaluated by a bivariate survival model. Results: A total of 29 trials reporting 2901 patients were included. ORR correlated with improved OS (3-year OS: 87.0% versus 70.4% for ORR versus non-ORR, respectively; HR, 0.34, 95% confidence interval [CI], 0.17-0.68). The HRs for OS in patients achieving MPR and pCR were 0.24 (95% CI, 0.12-0.46) and 0.13 (95% CI, 0.05-0.36). The survival benefit maintained after adjusting tumour type. C-statistics of ORR, MPR and pCR were 0.63, 0.63 and 0.65, respectively. The strength of association between RFS and OS was strong (R2 = 0.88, 95% CI, 0.79-0.94). Conclusions: These findings suggest that ORR, MPR, pCR and RFS are valid predictors for OS when using neoadjuvant immune checkpoint inhibitors. Moreover, MPR, pCR and RFS may be the most optimal surrogates for OS.
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China

Mingjun Rui,Zijing Wang,Zhengyang Fei,Yao Wu,Yingcheng Wang,Lei Sun,Ye Shang,Hongchao Li

DOI: https://doi.org/10.3389/fphar.2022.862640

IF: 5.6

2022-03-16

Frontiers in Pharmacology

Abstract:Objective: Due to the initiation of the priority review program in China, many antitumor drugs have been approved for marketing based on phase II clinical trials and short-term surrogate endpoint indicators. This study used approved targeted drugs for the treatment of non-small-cell lung cancer (NSCLC) in China as an example to evaluate the association between short-term surrogate endpoints [objective response rate (ORR) and disease control rate (DCR)] and median progression-free survival (mPFS) and median overall survival (mOS). Methods: Five databases, i.e., MEDLINE, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched, for phase II or phase III clinical trials of all molecular targeted drugs that have been marketed in China for the treatment of NSCLC. After screening the literature and extracting information, both univariate and multivariate linear regression were performed on the short-term surrogate indicators and mPFS and mOS to explore the relationship. Results: A total of 63 studies were included (25 studies with only ORR, DCR, and mPFS and 39 studies with ORR, DCR, mPFS, and mOS). In terms of the targeted drugs for the treatment of NSCLC, in addition to the good but not excellent linear relationship between DCR and mOS (0.4 < R 2 adj = 0.5653 < 0.6), all other short-term surrogate endpoint indicators had excellent linear relationships with mPFS and mOS (R 2 adj ≥0.6), while mPFS and mOS had the most excellent linear relationships (R 2 adj = 0.8036). Conclusion: For targeted drugs for the treatment of NSCLC, short-term surrogate endpoint indicators such as ORR and DCR may be reliable surrogate indicators for mPFS and mOS. However, whether short-term surrogate endpoint indicators can be used to predict final endpoints remains to be verified.

pharmacology & pharmacy
A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT

Xiaohui Zhang,Lin Chen,Han Jiang,Xuexin He,Liu Feng,Miaoqi Ni,Mindi Ma,Jing Wang,Teng Zhang,Shuang Wu,Rui Zhou,Chentao Jin,Kai Zhang,Wenbin Qian,Zexin Chen,Cheng Zhuo,Hong Zhang,Mei Tian

DOI: https://doi.org/10.1007/s00259-021-05572-0

2021-10-15

Abstract:Abstract Purpose This study aimed to develop a novel analytic approach based on 2-deoxy-2-[ 18 F]fluoro-D-glucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) radiomic signature (RS) and International Prognostic Index (IPI) to predict the progression-free survival (PFS) and overall survival (OS) of patients with diffuse large B-cell lymphoma (DLBCL). Methods We retrospectively enrolled 152 DLBCL patients and divided them into a training cohort ( n = 100) and a validation cohort ( n = 52). A total of 1245 radiomic features were extracted from the total metabolic tumor volume (TMTV) and the metabolic bulk volume (MBV) of pre-treatment PET/CT images. The least absolute shrinkage and selection operator (LASSO) algorithm was applied to develop the RS. Cox regression analysis was used to construct hybrid nomograms based on different RS and clinical variables. The performances of hybrid nomograms were evaluated using the time-dependent receiver operator characteristic (ROC) curve and the Hosmer–Lemeshow test. The clinical utilities of prediction nomograms were determined via decision curve analysis. The predictive efficiency of different RS, clinical variables, and hybrid nomograms was compared. Results The RS and IPI were identified as independent predictors of PFS and OS, and were selected to construct hybrid nomograms. Both TMTV- and MBV-based hybrid nomograms had significantly higher values of area under the curve (AUC) than IPI in training and validation cohorts (all P < 0.05), while no significant difference was found between TMTV- and MBV-based hybrid nomograms ( P > 0.05). The Hosmer–Lemeshow test showed that both TMTV- and MBV-based hybrid nomograms calibrated well in the training and validation cohorts (all P > 0.05). Decision curve analysis indicated that hybrid nomograms had higher net benefits than IPI. Conclusion The hybrid nomograms combining RS with IPI could significantly improve survival prediction in DLBCL. Radiomic analysis on MBV may serve as a potential approach for prognosis assessment in DLBCL. Trial registration NCT04317313. Registered March 16, 2020. Public site: https://clinicaltrials.gov/ct2/show/NCT04317313

radiology, nuclear medicine & medical imaging
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade

Li Wang,Li Liu,Jing Zhao,Xin Yu,Chunxia Su

DOI: https://doi.org/10.2147/ITT.S476040

2024-09-06

Abstract:Background: Immunotherapy has become the standard treatment for driving gene-negative advanced non-small cell lung cancer (NSCLC). However, compared to PD-L1-positive patients, the efficacy of Anti-PD-(L)1 monotherapy is suboptimal in PD-L1-negative advanced NSCLC. In this study, we aim to analyze the optimal immunotherapy approach for PD-L1-negative NSCLC patients and develop a new nomogram to enhance the clinical predictability of immunotherapy for NSCLC patients. Methods: In this study, we retrieved clinical information and genomic data from cBioPortal for NSCLC patients undergoing immunotherapy. Cox regression analyses were utilized to screen the clinical information and genomic data that related to survival. The prognostic-relate genes function was studied by comprehensive bioinformatics analyses. The Kaplan-Meier plot method was employed for survival analysis. Results: A total of 199 PD-L1-negative NSCLC patients were included in this study. Among them, 165 patients received Anti-PD-(L)1 monotherapy, while 34 patients received Anti-PD-(L)1+Anti-CTLA-4 combination therapy. The Anti-PD-(L)1+Anti-CTLA-4 combination therapy demonstrated significantly higher PFS compared to the Anti-PD-(L)1 monotherapy. The mutation status of KRAS, ANO1, COL14A1, LTBP1. ERBB4 and PCSK5 were found to correlate with PFS. Utilizing the clinicopathological parameters and genomic data of the patients, a novel nomogram was developed to predict the prognosis of Anti-PD-(L)1+Anti-CTLA-4 combination therapy. Conclusion: Our study revealed that KRAS, ANO1, COL14A1, LTBP1. ERBB4 and PCSK5 mutation could serve as predictive biomarkers for patients with Anti-PD-(L)1+Anti-CTLA-4 combination therapy. Our systematic nomogram demonstrates significant potential in predicting the prognosis for NSCLC patients with responsive to dual PD-1/CTLA-4 blockade.
Abstract 4967: Predicting progression-free survival (PFS) in first-line (1L) immune checkpoint inhibitor (ICI)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Machine learning (ML) application in real-world data

Deep K. Hathi,James Harnett,Ning Wu,Zhenxing Xu,Weishen Pan,T G. Hager,Ruben G. Quek,Shivani Aggarwal,Young Kim,Petra Rietschel,Frank Seebach,Fei Wang,Ying Li

DOI: https://doi.org/10.1158/1538-7445.am2024-4967

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Introduction: Anti-programmed cell death (ligand)-1 ICIs are the standard of care 1L treatment for pts with aNSCLC without actionable oncogenic driver mutations. Heterogeneity in ICI utilization and outcomes is observed in real-world pts. By leveraging ML in electronic health records (EHRs), we identified predictors influencing key clinical outcomes, and developed a nomogram to predict likelihood of median PFS in 1L ICI-treated aNSCLC pts for potential risk stratification for interventions. Methods: 1L ICI-treated aNSCLC pts without ALK/ROS1/KRAS/BRAF/EGFR alterations were identified in a US oncology EHR database (ConcertAI; Jan 2015-Feb 2023). Survival ML models were trained on 112 clinical and demographic features with 5-fold nested cross-validation. The top predictors, determined by the best-performing ML model through SHapley Additive exPlanations and clinical judgement, were used to create a Cox proportional hazard (CPH) nomogram of median PFS. All models were evaluated using the concordance index (c-index). Patients were categorized as having high and low risk of progression/death at median PFS according to median risk predicted by the nomogram. Results: The study cohort had 4668 pts (median PFS: 6.1 months; 3811 events). The CPH nomogram predicting 6-month PFS had a c-index of 0.60 with the top 10 predictors identified using the XGBoost model (c-index: 0.62). Nomogram predictors included increased number of metastases, ECOG PS, cough suppressant use, WBC counts, and NLR (Table). Median probability of 6-month PFS for low- and high-risk groups was 35.9% and 19.4%, respectively. Conclusions: Future research should validate these findings and evaluate the opportunity to guide clinical practice to optimize outcomes in aNSCLC pts treated with 1L ICIs. Summary of top 10 clinical predictors at baseline Mean HR (95% CI) Max nomogram points Total metastases, n 1.15 (1.11-1.19) 100 ECOG PS, ordinal 1.14 (1.10-1.19) 55 Basophils, % 0.81 (0.73-0.90) 52 Albumin, g/dL 0.81 (0.75-0.87) 46 Chloride, mmol/L 0.98 (0.97-0.99) 46 Cough suppressants/expectorants, n 1.08 (1.03-1.14) 42 NLR 1.03 (1.02-1.05) 33 WBC counts, 103 cells/mL 1.02 (1.01-1.03) 29 PD-L1 expression, % 1.00 (1.00-1.00) 28 Presence of liver metastases 1.26 (1.15-1.39) 24 ECOG PS, Eastern Cooperative Oncology Group performance status; NLR, neutrophils-to-lymphocytes ratio; PD-L1, programmed cell death-ligand 1; WBC, white blood cell. Citation Format: Deep K. Hathi, James Harnett, Ning Wu, Zhenxing Xu, Weishen Pan, T G. Hager, Ruben G. Quek, Shivani Aggarwal, Young Kim, Petra Rietschel, Frank Seebach, Fei Wang, Ying Li. Predicting progression-free survival (PFS) in first-line (1L) immune checkpoint inhibitor (ICI)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Machine learning (ML) application in real-world data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4967.

oncology
Assessing clinical response in early oncology development with a predictive biomarker

Shibing Deng,Feng Liu,Jadwiga Bienkowska,Shibing DengFeng LiuJadwiga Bienkowskaa Translational Biomarker Statistics,Pfizer Research & Development,La Jolla,CAb Oncology Research & Development,Pfizer Inc,La Jolla,CAc ComputationalBiology,Oncology Research & Development,Pfizer Inc,La Jolla,CA

DOI: https://doi.org/10.1080/10543406.2024.2330207

2024-03-23

Journal of Biopharmaceutical Statistics

Abstract:In early oncology clinical trials there is often limited data for biomarkers and their association with response to treatment. Thus, it is challenging to decide whether a biomarker should be used for patient selection and enrollment. Most evidence about any potential predictive biomarker comes from preclinical research and, sometimes, clinical observations. How to translate the preclinical predictive biomarker data to clinical study remains an active field of research. Here, we propose a method to incorporate existing knowledge about a predictive biomarker – its prevalence, association with response and the performance of the assay used to measure the biomarker – to estimate the response rate in a clinical study designed with or without using the predictive biomarker. Importantly, we quantify the uncertainty associated with the biomarker and its predictability in a probabilistic model. This model estimates the distribution of the clinical response when a predictive biomarker is used to select patients and compares it to unselected cohort. We applied this method to two real world cases of approved biomarker-guided therapies to demonstrate its utility and potential value. This approach helps to make a data-driven decision whether to select patients with a predictive biomarker in early oncology clinical development.

pharmacology & pharmacy,statistics & probability
Cilastatin does not alter superoxide dismutase activity

R. Proctor,J. Textor

DOI: https://doi.org/10.1128/AAC.28.5.691

IF: 5.938

1985-11-01

Antimicrobial Agents and Chemotherapy

Abstract:Cilastatin inhibits dehydropeptidase-I, a zinc metaloenzyme that metabolizes imipenem. Because zinc stabilizes the mammalian superoxide dismutase, we postulated that cilastatin would also inhibit the dismutase. Cilastatin concentrations at levels threefold higher than those expected in urine, however, did not inhibit the superoxide dismutase activity.

Immunological studies in patients receiving Corynebacterium parvum (C.P.) as immunotherapy for acute myelogenous leukemia (AML).

Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated with Anti-Pd-1 Antibody

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Abstract 6401: Predictive models for first-line immunotherapy based on spatial tumor immune microenvironment in patients with advanced non-small cell lung cancer (NSCLC)

951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis

Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models

Abstract 6904: Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies

Hypoxia-mediated in vivo release of dopamine in nucleus tractus solitarii of rabbits.

Stomatogenic function of the micronucleus in Paramecium jenningsi.

Risk Models For Advanced Melanoma Patients Under Anti-Pd-1 Monotherapy-Ad Hoc Analyses Of Pooled Data From Two Clinical Trials

Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncology

Abstract 5697: Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data

Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China

A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT

Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade

Abstract 4967: Predicting progression-free survival (PFS) in first-line (1L) immune checkpoint inhibitor (ICI)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Machine learning (ML) application in real-world data

Assessing clinical response in early oncology development with a predictive biomarker

Cilastatin does not alter superoxide dismutase activity